Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025 - 2026)
Tg Therapeutics' (TGTX) quarterly Long-Term Deferred Tax came in at $344.1 million in Q1 2026, down 1.11% quarter-over-quarter from $348.0 million in Q4 2025.
Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Tg Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $344.1 million for Q1 2026.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $344.1 million in Q1 2026; TTM through Mar 2026 was $344.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $348.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax fell to $344.1 million in Q1 2026 per TGTX's latest filing, from $348.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $366.6 million in Q3 2025 and bottomed at $344.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tg Therapeutics | 8.88 Bn | 8.80 Bn | 171.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 344.14 Mn |
| Dec 31, 2025 | 348.00 Mn |
| Sep 30, 2025 | 366.63 Mn |